BRPI0507897A - formulação de droga sólida - Google Patents

formulação de droga sólida

Info

Publication number
BRPI0507897A
BRPI0507897A BRPI0507897-0A BRPI0507897A BRPI0507897A BR PI0507897 A BRPI0507897 A BR PI0507897A BR PI0507897 A BRPI0507897 A BR PI0507897A BR PI0507897 A BRPI0507897 A BR PI0507897A
Authority
BR
Brazil
Prior art keywords
drug formulation
solid drug
deaminoidoxy
toremifene
stereoisomer
Prior art date
Application number
BRPI0507897-0A
Other languages
English (en)
Inventor
Veli-Matti Lehtola
Kaija Halonen
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34861126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of BRPI0507897A publication Critical patent/BRPI0507897A/pt
Publication of BRPI0507897B1 publication Critical patent/BRPI0507897B1/pt
Publication of BRPI0507897B8 publication Critical patent/BRPI0507897B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO DE DROGA SóLIDA A invenção refere-se a uma formulação de droga sólida, que compreende grânulos contendo ospemifeno (também conhecido como (deaminoidróxi) toremifeno) como um composto terapeuticamente ativo, ou um isómero geométrico, um estereoisómero, um sal farmaceuticamente aceitável, ou um éster do mesmo, ou um metabólito do mesmo, em combinação com um ou mais excipientes intra-granulares.
BRPI0507897A 2004-02-23 2005-01-19 formulação de droga sólida BRPI0507897B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/783,024 US8642079B2 (en) 2004-02-23 2004-02-23 Solid formulations of ospemifene
PCT/FI2005/000037 WO2005079777A1 (en) 2004-02-23 2005-01-19 Solid formulations of ospemifene

Publications (3)

Publication Number Publication Date
BRPI0507897A true BRPI0507897A (pt) 2007-07-24
BRPI0507897B1 BRPI0507897B1 (pt) 2018-10-09
BRPI0507897B8 BRPI0507897B8 (pt) 2021-05-25

Family

ID=34861126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507897A BRPI0507897B8 (pt) 2004-02-23 2005-01-19 formulação de droga sólida

Country Status (19)

Country Link
US (2) US8642079B2 (pt)
EP (2) EP2286806A1 (pt)
JP (1) JP4993203B2 (pt)
CN (1) CN1953741B (pt)
AT (1) ATE506054T1 (pt)
AU (1) AU2005215174B2 (pt)
BR (1) BRPI0507897B8 (pt)
CA (1) CA2554695C (pt)
CY (1) CY1111689T1 (pt)
DE (1) DE602005027540D1 (pt)
DK (1) DK1718288T3 (pt)
ES (1) ES2364970T3 (pt)
MX (1) MXPA06009546A (pt)
NO (1) NO341573B1 (pt)
PL (1) PL1718288T3 (pt)
PT (1) PT1718288E (pt)
RU (2) RU2675624C2 (pt)
SI (1) SI1718288T1 (pt)
WO (1) WO2005079777A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
ES2392344T3 (es) 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
BRPI0618510A2 (pt) * 2005-11-09 2011-09-06 Hormos Medical Ltd formulação medicamentosa lìquida ou semi-sólida
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
ES2590262T3 (es) 2007-02-14 2016-11-21 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
US20110028480A1 (en) * 2008-04-01 2011-02-03 Ocean 1 806, Llc Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型
US20160000732A1 (en) * 2014-07-02 2016-01-07 Cadila Healthcare Limited Oral pharmaceutical compositions of ospemifene
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
US10138190B2 (en) 2015-01-09 2018-11-27 Glenmark Pharmaceuticals Limited Process for preparation of ospemifene
MX2017011469A (es) * 2015-03-10 2018-01-23 Shionogi Inc Dispersiones sólidas.
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PL3573472T3 (pl) * 2017-01-24 2025-02-24 OmniGen Research, L.L.C. Granulowany suplement paszowy oraz sposoby wytwarzania i zastosowania
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117121A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. Method of increasing bile flow and decreasing lipid levels
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
AU718417B2 (en) * 1995-11-14 2000-04-13 Stockhausen Gmbh & Co. Kg Water additive and method for fire prevention and fire extinguishing
GB9604577D0 (en) * 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
FI101305B1 (fi) * 1996-03-18 1998-05-29 Map Medical Technologies Oy Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatsepiini-johdannaiset ja niiden käyttö diagnostiikassa
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
RU2112504C1 (ru) * 1996-12-24 1998-06-10 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Средство для лечения заболеваний предстательной железы "витапрост"
WO2000004880A1 (en) * 1998-07-23 2000-02-03 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
RU2177802C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения
US20030055075A1 (en) * 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
WO2003015820A1 (en) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
NZ536118A (en) 2002-06-06 2007-08-31 Hormos Medical Ltd Method for the inhibition of urogenital atrophy or for treatment or prevention of urogenital atrophy-related symptoms in women
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
EA200700760A1 (ru) * 2007-04-27 2008-08-29 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Средство для лечения заболеваний предстательной железы
RU2430733C2 (ru) * 2009-10-08 2011-10-10 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты)

Also Published As

Publication number Publication date
WO2005079777A1 (en) 2005-09-01
SI1718288T1 (sl) 2011-09-30
CN1953741B (zh) 2011-03-30
PT1718288E (pt) 2011-07-25
DE602005027540D1 (de) 2011-06-01
MXPA06009546A (es) 2007-04-10
BRPI0507897B1 (pt) 2018-10-09
RU2675624C2 (ru) 2018-12-21
CY1111689T1 (el) 2015-10-07
RU2423113C2 (ru) 2011-07-10
PL1718288T3 (pl) 2011-10-31
EP2286806A1 (en) 2011-02-23
DK1718288T3 (da) 2011-08-01
CA2554695C (en) 2013-03-05
AU2005215174B2 (en) 2010-06-03
US8642079B2 (en) 2014-02-04
RU2011112362A (ru) 2012-10-10
BRPI0507897B8 (pt) 2021-05-25
AU2005215174A1 (en) 2005-09-01
RU2006133902A (ru) 2008-03-27
US20140220118A1 (en) 2014-08-07
ATE506054T1 (de) 2011-05-15
CN1953741A (zh) 2007-04-25
US20050187301A1 (en) 2005-08-25
EP1718288B1 (en) 2011-04-20
JP4993203B2 (ja) 2012-08-08
ES2364970T3 (es) 2011-09-19
EP1718288A1 (en) 2006-11-08
JP2007523210A (ja) 2007-08-16
NO20064262L (no) 2006-09-20
CA2554695A1 (en) 2005-09-01
NO341573B1 (no) 2017-12-04

Similar Documents

Publication Publication Date Title
BRPI0507897B8 (pt) formulação de droga sólida
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
TN2012000216A1 (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
PT2038290E (pt) Moduladores de receptor do tipo toll 7
EA201170703A1 (ru) Производные адамантилбензамида
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
MX2009012779A (es) Derivado de tetrahidroisoquinolin-1-ona o sal de el.
CU23850B1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
NO20082181L (no) Formuleringer av Fispemifen
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
NO20064808L (no) Orale matrixformuleringer med licarbazepin
BRPI0518426A2 (pt) composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes
BRPI0510465A (pt) formulação de droga oral semi-sólida ou lìquida
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
SE0203817D0 (sv) New composition
DE602006016621D1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
WO2007093168A3 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2758 DE 14-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.